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Background:  Adamantanes impede influenza A virus replication and are important in the treatment and prophylaxis 
of disease caused by these viruses. Genotypic characterization of influenza A viruses for mutations associated with 
resistance to adamantanes has not been fully investigated in Kenya. 
Objective:  To characterize susceptibility of influenza A virus subtypes that circulated in Kenya from 2008-2011 to 
adamantanes.   
Methods:  Archived influenza A virus strains obtained from 2008 to 2011 were propagated in MDCK cells prior to 
sequencing of the matrix and hemagglutinin gene segments, followed by bioinformatics analyses.  
Results:  Ninety two virus strains consisting of 21 A/H3N2, 18 A/H1N1 and 53 A/H1N1pdm09 were analyzed.  All 
A/H3N2 and A/H1N1pdm09 viruses displayed resistance to adamantanes due to the S31N/S31D amino acid 
substitution. All A/H1N1pdm09 virus strains belonged to the N-lineage characterized by S203T amino acid 
substitution in the HA1. All A/H1N1 viruses were sensitive to adamantane and were characterized by K140E amino 
acid substitution in the HA1.  
Conclusion: All Kenyan influenza A/H3N2 and A/H1N1pdm09 virus strains were resistant to adamantanes while 
seasonal A/H1N1 strains were sensitive to these drugs. During the study period, Amantadine and Rimantadine were 
inappropriate for prophylaxis and treatment of influenza disease caused by A/H3N2 and A/H1N1pdm09 virus 
subtypes in Kenya. 
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1. Introduction 
Influenza type A viruses cause serious respiratory 
disease. The illness can begin as sub-clinical infection 
and graduate to primary viral pneumonia.  It can cause 
death in humans and this is determined by several 
factors including age of the patient, immune status of the 
patients, and virulence of the influenza A virus strain. 
The elderly aged > 65 years and children aged < 2 years 
are at a greater risk of developing complications from 
influenza(Rothberg et al, 2008). The disease manifests 
with severe outcomes in patients whose immune system 
is compromised as well as pregnant women.  Certain 
strains with mutations in key virulence factors of the 
virus also lead to a severe outcome of diseases. Genes 
encoding the HA, NA, and PB1 proteins, significantly 
contribute to replication efficiency and virulence 
(Taubenberger et al, 2012).  According to the CDC, the 
global annual morbidity and mortality rates due to 
influenza epidemics stand at 3.5 million cases of severe 
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illness and 300,000 to 500,000 deaths (CDC, 2015). In 
addition, influenza A viruses are responsible for 
infrequent but severe pandemics which can affect 
greater than 50% of the population in a single year 
(Palese & Lowen, 2007).  
The use of antiviral drugs to treat illness and reduce 
transmission of the virus is essential in the early phase of 
a pandemic (Monto, 2003, Monto, 2006, Stohr, 2003) 
because it buys time prior to production and availability 
of a vaccine against the pandemic strain in sufficient 
quantities for mass vaccination. In fact, it has been shown 
through simulation of an influenza outbreak in Southeast 
Asia, that it may be possible to contain an emerging 
pandemic at the start if appropriate, targeted antiviral 
prophylaxis is applied (Ferguson et al, 2005, Longini et 
al, 2004). Thus the need for new and constant evaluation 
of efficacy of existing antiviral drugs through 
surveillance of resistance to such drugs cannot be 
overstated. 
Characterization of human influenza A subtypes 
illustrated the dominance of two particular strains: 
A/H1N1 and A/H3N2 in seasonal epidemics and 
occasional pandemics within human populations prior to 
2009.  In 2009 a novel strain, influenza A/H1N1pdm09 
emerged and this strain has continued to co-circulate 
and has completely replaced seasonal influenza 
A/H1N1(Broor et al, 2012). Therefore, the 2008-2011 
time period provided a distinctive period when for the 
first time three human influenza A virus subtypes co-
circulated.  Antivirals are vital in the management of 
influenza infections because unlike vaccines, they have a 
direct effect on the viral agent making them important 
tools for mitigating influenza disease outcomes as well as 
prophylaxis (Moscona, 2008). Two main classes of 
antivirals have been used in the control of influenza: 
Adamantane-derived M2 ion channel blockers 
(amantadine and rimantadine) which are only effective 
against influenza A viruses and neuraminidase inhibitors 
mainly oseltamivir and zanamivir (Okomo-Adhiambo et 
al, 2010) which are efficacious against both influenza A 
and B subtypes. M2 ion channel blockers inhibit the 
uncoating of the virus through acidification of the 
interior of the virion (Holsinger et al, 1994). Currently 
there is a major concern regarding increasing resistance 
to antivirals. Regular use of antivirals has been shown to 
promote the development of antiviral resistance in the 
population due to positive selection (Garcia & Aris-
Brosou, 2013).  Antiviral resistance can also be acquired 
via transmission in which resistant strains replace 
susceptible strains in the absence of drug pressure. This 
transmission has been observed in the global spread of 
adamantine resistant A/H3N2 viruses since 2003 
(Hayden & de Jong, 2011). These premises provide the 
necessity for a better understanding and 
characterization of antiviral resistance to circulating 
influenza A viruses.  The discovery of antiviral resistance 
to both classes of antiviral agents posed a serious threat 
to the management of influenza viruses not only because 
treatment was being rendered ineffective, but also 
because it was discovered that this resistance was being 
transmitted to other regions, even where occurrences of 
the virus had not been documented (Hayden & de Jong, 
2011). 
Currently, there exists no data on antiviral drug 
susceptibility patterns within the sub-Saharan Africa.  
Genotypic characterization of mutations causing 
antiviral resistance in these regions has not been 
investigated fully. To bridge this gap, we characterized 
antiviral susceptibility of influenza A viruses to M2 
blockers using known molecular markers and report on 
susceptibility of the three major human influenza A 
subtypes to these drugs in Kenya between the years 
2008 and 2011, a unique period when these three 
distinct human influenza A subtypes co-circulated in the 
country. 
2. Materials and Methods 
2.1 Specimen collection and transportation 
The influenza A isolates were derived from samples 
obtained from outpatients in district hospitals 
constituting the sentinel sites of the USAMRU-K 
Influenza Surveillance Network in Kenya. Samples were 
obtained by trained clinicians after the necessary 
consenting process. The case definition consisted of 
being outpatients of age ≥ 2 months, having a fever of 
38ºC and above, with a cough or sore throat and 
presenting within 72 hrs after the onset of symptoms. 
Duplicate nasopharyngeal swabs were collected and 
placed in the viral transport media and stored at 2 – 8ºC 
for not more than 8 hours.  For midterm storage, samples 
were snap-frozen in liquid nitrogen and transported to 
the central National Influenza Center laboratory in 
Nairobi for analysis and storage in the ultra-low freezer 
(-65 to -85ºC). 
2.2 Diagnostic test for influenza A subtypes by real-
time reverse transcription polymerase chain 
reaction  
Virus RNA was extracted from patient samples using 
QIAamp Viral RNA extraction kit (Qiagen, Germany) 
following the manufacturer’s protocol. Briefly, 100μl of 
the NP sample was added to 500μl of lysis buffer per tube 
and allowed to incubate at room temperature for 10 
minutes to allow for the lysis. 500μl of ethanol was then 
added and pulse vortexed for 15 seconds resulting in a 
homogeneous lysate. 630μl of the lysate was applied to 
the spin columns and centrifuged at 595(x-g) for 1 
minute and the column placed in a clean collection tube. 
500μl of Buffer AW1 (wash buffer 1) was added to the 
spin column and centrifuged at 595(x-g) for 1 minute 
and the column placed in a clean collection tube. The 
column was then washed with 500μl of Buffer AW2 
(wash buffer 2) and centrifuged at 1620 (x-g) for 3 
minutes. The spin column was then placed in a 1.5 ml 
micro centrifuge tube and 60 μl of Buffer AVE (elution 
buffer) added to the column and allowed to incubate for 
1 minute. The column was then centrifuged at 595 (x-g) 
for 1 minute and the filtrate (RNA) stored at -200C. 
Presence of influenza A virus in patient samples was 
carried out by real-time reverse transcription 
polymerase chain reaction (RRT-PCR) assay, utilizing the 
Matrix gene-specific Uni12 primer  set and probe 
(Hoffmann et al, 2001).  Preliminary detection of 
seasonal influenza A/HI, seasonal influenza A/H3 and 
pandemic influenza A/H1 from viral laden 
nasopharyngeal swabs were determined by RRT-PCR 
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assay on an ABI Prism 9700 thermocycler (Applied 
Biosystems, Foster City, CA USA). This was performed 
using subtype-specific primer sets for hemagglutinin 
genes of influenza A viruses. All primer sets and probes 
were developed by the Centers for Disease Control and 
Prevention (CDC), Atlanta.  
2.3 Virus isolation and serotyping 
Viruses were isolated from NP samples that tested 
positive for influenza A viruses.  This was performed in 
Madin-Darby canine kidney (MDCK) cells obtained from 
American Type Cell Culture (Manassas, VA. USA). The 
MDCK cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (Sigma Aldrich, St. Louis, USA) supplemented 
with 4.5g/L glucose and 10% Fetal Bovine Serum (FBS), 
1% sodium pyruvate, 1% penicillin-streptomycin 
solution and 1% glutamine (Sigma Aldrich, St. Louis, 
USA). The cells were grown as monolayers in flat sided 
tissue culture tubes. 100 μl of each sample were 
inoculated onto 70-90% confluent MDCK cells in flat 
sided tubes after pre-treatment with TPCK trypsin 
(2mg/ml) (Sigma, Missouri, USA) in order to facilitate 
virus entry into the cells.  Tubes were incubated with the 
caps loose in a tissue culture incubator at 37°C under 5% 
CO2.  Tubes were observed daily for 10 days for visual 
cytopathic effect (CPE) by light microscopy using an 
inverted microscope (Olympus, Tokyo, Japan). When the 
CPE was clear, supernatant fluid was collected and tested 
for hemagglutination titer, and when sufficient, 
hemagglutination inhibition (HAI) testing was 
conducted in accordance with CDC protocols using 
guinea pig red blood cells and 2008 - 2011 reference 
reagents for influenza virus diagnosis from a WHO kit 
provided by the Center for Disease Control (CDC), 
Atlanta.  
2.4 Sequencing of the M and HA gene segments of 
Influenza A viruses 
To identify key mutations associated with adamantine 
resistance, we used genotypic methods. Preliminary 
genotyping involved targeted amplification of matrix (M) 
and HA genes by standard PCR method using RNA 
extracted from the human influenza A/H3N2, influenza 
A/H1N1 and influenza A/H1N1pdm09 isolates. 
Extraction of RNA from isolates was performed as 
outlined earlier using QIAamp Viral RNA extraction kit 
(Qiagen, Hilden, Germany) in accordance with the 
manufacturer’s protocol.  
Reverse transcriptase PCR (RT-PCR) was performed 
using Superscript III One-Step RT-PCR system 
(Invitrogen, Carlsbad, USA)) with primers specific for M 
and HA genes of human A/H1N1pdm09, H3N2 and H1N1 
subtypes. The primer sequences were provided by CDC 
Atlanta. A single reaction consisted of 12.5µl of 2x 
reaction mix; 0.5µl each of both sense and antisense 
primers reconstituted to 20µM concentration; 1.0µl of 
Superscript III RT/Platinum Taq Mix and 3µl of RNA 
template in a 25µl reaction mixture. All the RT PCR 
reagents were sourced from Invitrogen, Carlsbad, USA.   
Thermocycling conditions on the 9700 Fast ABI 
thermocycler included 1 cycle of reverse transcription at 
500C for 30 minutes followed by denaturation at 940C for 
30 seconds, primer annealing at 550C for 30 seconds and 
strand synthesis at 680C for 1 minute for 35 cycles.  This 
was followed by a final strand extension at 680C for 1min. 
Purification of sequencing amplicons was performed 
using ExoSAP-IT (USB Corporation, town city).  
Nucleotide sequences of the PCR amplicons were 
determined using the BigDye Terminator cycle 
sequencing Kit (version 3.1) (Applied Biosystems, Foster 
City, USA). Purification of labeled amplicons was 
performed using Sephadex gel (Sigma Aldrich, St. Louis, 
USA) filtration prior to loading and running on the 
3500xL Genetic Analyzer (Applied Biosystems, Foster 
City, CA, USA). Sequence assembly was carried out using 
DNA Baser tool (DNA Baser Sequence Assembler v4). 
Raw sequence curation and preliminary alignment of M 
and HA gene sequences was carried out using the BioEdit 
suite run under default parameters.  All the sequences 
reported here have been deposited in the GenBank and 
GISAID databases under accession numbers: 
GenBank database 
KX431150 - KX431168; HQ214406; HQ214407; 
HQ214418; HQ214422; HQ214423; HQ214429; 
HQ214432; HQ214437; HQ214441; HQ214444; 
HQ214449; HQ214453 for the M genes  
KX431169 - KX431203; HM347404-HM347412; 
HM347414; HM347417-HM347422; HM347424; 
HM347361-HM347380; HM347382-HM347392 for the 
HA genes. 
GISAID database 
EPI400061; EPI356798; EPI356813; EPI356816; 
EPI356870; EPI356873; EPI356876; EPI356889 
EPI356897; EPI356907; EPI356915; EPI356926; 
EPI357513 for the HA genes 
EPI400063; EPI356800; EPI356815; EPI356818; 
EPI356872; EPI356875; EPI356878; EPI356891; 
EPI356900;EPI356909; EPI356917; EPI356929; 
EPI357518 for the M genes. 
2.5 Genetic characterization and phylogenetic 
analysis 
The nucleotide sequences of the M genes were spliced to 
give the M2 gene segments.  Selection of global M2 and 
HA sequences from Gene bank for inclusion in the 
alignments was accomplished using the basic local 
alignment search tool (BLAST) with the default 
parameters of the program (Altschul et al, 1997). 
Nucleotide sequences of the gene segments and selected 
sequences were translated into protein code using 
discovery studio gene (DS Gene) V1.5 (Accelrys Inc., 
Oxford, UK) applying the universal genetic code. To 
determine presence or absence of known molecular 
markers of antiviral susceptibility, protein multiple 
sequence alignments of M2 proteins were performed 
using the Multiple Sequence Comparison by Log-
Expectation (MUSCLE) V3.8 (Edgar, 2004a, Edgar, 
2004c). Aligned sequences were visualized using 
GeneDoc (Nicholas & Nicholas). 
The phylogenetic reconstruction was carried out using 
the Bayesian method of tree inference which makes use 
of the MrBayes program (Ronquist & Huelsenbeck, 
2003). Aligned protein data in the fasta format was 
converted into the Nexus format using the Concatenator 
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program (Pina‐Martins & Paulo, 2008). The nexus file 
incorporating the GTR model code was executed in 
MrBayes by running 1000000 Monte Carlo Markov 
Chains (MCMC) with a sampling frequency of 1000 trees. 
Consensus trees were generated and visualized using 
FigTree V1.3.1 (Rambaut, 2009) 
2.6 Ethical considerations 
All ethical requirements were adhered to during 
specimen collection as outlined in the parent protocols 
for Walter Reed Army Institute of Research (WRAIR 
protocol # 1267) and Kenya Medical Research Institute 
(KEMRI SSC #981).  
Specimen processing and analysis was carried out using 
the guidelines from WRAIR protocol # 1990 (sub-project 
4) and KEMRI SSC # 2243. 
 
 
3.  Results  
Susceptibility of influenza A viruses circulating in 
Kenya 2008-2011 to M2-inhibitors 
From the peculiar study period of 2008-2011 when the 
three human influenza subtypes co-circulated in Kenya, 
we analyzed 92 M2 protein sequences of influenza A 
viruses consisting of 21 fragments for influenza A/H3N2, 
18 for seasonal influenza A/H1N1 and 53 for influenza 
A/H1N1pdm09. All the M2 proteins of influenza A/H3N2 
and influenza A/H1N1pdm09 virus subtypes analyzed 
possessed an S31N substitution (Fig. 1). One virus isolate 
of influenza A/H3N2 subtype designated 
KEN/164/2011 possessed 4 mutations indicated as 
L26I, V27S, A30C and S31D substitution. Furthermore a 
single influenza Mutation analyses for M2 protein 
sequences amongst the 18 seasonal influenza A/H1N1 
viruses showed absence of all drug-specific substitutions 
(Figure 1).   
Figure 1: An alignment showing mutations in selected positions of M2 sequences of influenza A/H3N2, A/H1N1 and 
A/H1N1pdm09.  
The S31N marker of drug resistance was dominant in the influenza A/H3N2 and A/H1N1pdm09 virus subtypes. Vaccine 
strains-A/California/07/2009, A/Solomon Island/3/2006, A/Brisbane/59/2007, A/Brisbane/10/2007 and 
A/Perth/16/2009- are included in the alignment. 
 
4 9 11 13 14 16 20 21 23 24 25 26 27 28 29 30 31 36 43 48 49 50 51 52 54 57 58 59 61 63 77 78 82 86 89 93 95
KEN 201 2010H3 V P T S E E N D S D P L V I A A N L T F K C I Y R Y G L R P Q Q S V G N E
KEN 29 2011P L T . . . . S . . N . . . . . . . . . . . . . . . . V . . . . . . . . . .
KEN 10 2011P L T . . . . S . . . . . . . . . . . . . . . . . . . V . . . . . . . . . .
KEN 62 2009P L T . . . . S . . . . . . . . . . . . . . . . . . . V . . . . . . . . . .
KEN 32 2011P L T . . . . S . . . . . . . . . . . . . . . . . . . V . . . . . . . . . .
KEN 105 2009P L T . . . . S . . . S . . . . . . . . . . . . . . . . . . . . . . . . . .
KEN 206 2010H3 L T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
KEN 209 2010H3 L T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Kenya 196 2011P L T . . . . S G . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
KEN 125 2009 L T . . . . S . . . . . . . . . . . . . . . . H . . . . . . . . . . . . .
KEN 102 2009P L T . . . . S . . . . . . . . . . . . . . . . H . . . . . . . . . . . . .
A California 07 2009P L T . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
KEN 61 2009P L T . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
KEN 63 2010P L T . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
KEN 96 2009P L T . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
KEN 87 2009P L T . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
KEN 121 2009P L T . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
KEN 108 2009P L T . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
KEN 100 2009P L T . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
KEN 97 2009P L T . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
KEN 126 2009P L T . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
KEN 71 2009P L T . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
KEN 118 2009P L T . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
A Solomon Islands 3 2006H1 L T I N . G . . . . . . . V . . S V I S . S . . I H . . G . R E N A . S .
KEN 22 2008H1 L T I N . G . . . . . . . V . . S V I S Q S . . I H . . . . R E N A D S .
KEN 21 2008H1 L T I N . G . . . . . . . V . . S V I S Q S . . I H . . . . R E N A D S .
KEN 23 2008H1 L T I N . G . . . . . . . V . . S V I S Q S . . I H . . . . R E N A D S .
KEN 08 2009H1 L T I N G G . . . . . . . V . . S V I S . S . . I H . . . . R E N A D S .
A Brisbane 59 2007H1 L T I N . G . . . . . . . V . . S V I S . S . . I H . . . . R E N A D S .
KEN 18 2009H1 L T I N . G . . . . . . . V . . S V I S . S . . I H . . . . R E N A D S .
KEN 35 2009H1 L T I N . G . . . . . . . V . . S V I S . S . . I H . . . . R E N A D S .
KEN 06 2009H1 L T I N . G . . . . . . . V . . S V I S . S . . I H . . . . R E N A D S .
KEN 15 2009H1 L T I N . G . . . . . . . V . . S V I S . S . . I H . . . . R E N A D S .
KEN 25 2009H1 L T I N . G . . . . . . . V . . S V I S . S . . I H . . . . R E N A D S .
KEN 30 2009H1 L T I N . G . . . . . . . V . . S V I S . S . . I H . . . . R E N A D S .
KEN 39 2009H1 L T I N . G . . . . . . . V . . S V I S . S . . I H . . . . R E N A D S .
KEN 164 2011H3 L T I N . G . . N E V I S V S C D . L . . . V . L H . . . . R K N A S S .
KEN 203 2010H3 L T I N . G . . . E . . . V . . . . L . . . V . L H . . . H R K N A S S .
KEN 01 2008H3 L T I N . G . . . . . . . V . . . . L . . . V . L H . . . . R K N A S S K
A Perth 16 2009H3 L T I N . G . . . . . . . V . . . . L . . . V . L H . . . . R K N A S S .
A Brisbane 10 2007H3 L T I N . G . . . . . . . V . . . . L . . . V . L H . . . . R K N A S S .
KEN 154 2011H3 L T I N . G . . . . . . . V . . . . L . . . V . L H . F . . R K N A S S .
KEN 160 2011H3 L T I N . G . . . . . . . V . . . . L . . . V . L H . F . . R K N A S S .
KEN 161 2011H3 L T I N . G . . . . . . . V . . . . L . . . V . L H . F . . R K N A S S .
KEN 152 2011H3 L T I N . G . . . . . . . V . . . . L . . . V . L H . F . . R K N A S S .
KEN 156 2011H3 L T I N . G . . N . . . . V . . . . L . . . V . L H . F . . R K N A S S .
KEN 159 2011H3 L T I N . G . . N . . . . V . . . . L . . . V . L H . . . . R K N A S S .
KEN 158 2011H3 L T I N . G . . N . . . . V . . . . L . . . V . L H . . . . R K N A S S .
KEN 157 2011H3 L T I N . G . . N . . . . V . . . . L . . . V . L H . . . . R K N A S S .
Iso late strains A mino  acid subst itut io n po sit io ns in M 2 pro tein o f  inf luenza H 3N 2,sH 1N 1 and H 1N 1pdm09
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Figure 2: Phylogenetic tree analysis of M2 amino sequences of influenza A/H3N2, A/H1N1 and A/H1N1pdm09 virus 
isolates from Kenya.  
The virus strains were obtained between 2009-2011. Amino acid substitutions determined are indicated at the node. 
Pyhlogenetic tree was inferred by running one million Monte Carlo Markov Chains (MCMC) with a sampling frequency 
of 1000 trees. A consensus tree for M2 sequences was generated and visualized using FigTree version 1.3.1. Reference 
vaccine strains for influenza A/H3N2, A/H1N1 and A/H1N1pdm09 virus subtypes are highlighted in green, brown and 
blue colours respectively. Three dominant clusters are evident: One consisting of influenza A/H1N1pdm09 and two 
influenza A/H3N2 virus strains characterized by V28I and G16E substitutions; second cluster formed by influenza 
A/H1N1 strains and possessing L36V and T43I amino acid changes; third cluster of influenza A/H3N2 virus strains 
distinguished by T43L and I51V substitutions. 
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Figure 3: Phylogenetic tree of HA1 amino sequences of influenza A/H3N2 virus strains obtained between 2009-2011. 
The vaccine strains A/Perth/16/2009 and A/Brisbane/10/2007 are highlighted in red. The strains from Kenya are 
highlighted in blue while global strains have been highlighted in black. All Kenyan viruses were defined by K140T and 
S193F amino acid substitutions in their HA1 gene. 
 
The tree topology showing the genetic clustering of the 
M2 sequences (Figure 2) revealed three clusters with 
each virus subtype forming a distinct cluster. However, 
two virus strains of influenza A/H3N2 clustered with the 
A/H1N1pdm09 virus strains.  Virus strains of influenza 
A/H3N2 and influenza A/H1N1 clustered on the same 
main branch as a result of sharing T11I and I28V 
substitutions. However, the two subtypes diverged from 
each other due to the presence of I15V, T43L & R54L 
amongst the A/H3N2 viruses and L36V & T43I 
substitutions amongst the A/H1N1 viruses. All the 
Kenyan influenza A/H1N1pdm09 viruses, together with 
two influenza A/H3N2 virus strains: KEN_201_2010, 
KEN_206_2010 and KEN_209_2010 formed a separate 
cluster characterized by the amino acid substitutions 
I11T, N13S, G16E, V28I and I54R (Figure 2). 
Phylogenetic analysis of HA1 protein sequences in 
relation to adamantane drug resistance. 
To identify the origin and possible reassortment of 
adamantane resistance amongst the Kenyan viruses, we 
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performed phylogenetic analyses of the viruses using the 
HA1 gene segment of the viruses.  HA1 is used to 
delineate the subtype assignment amongst influenza A 
viruses.  Phylogenetic analysis of the HA1 protein of 
influenza A/H3N2 (Fig.3), revealed 2 distinct clades each 
consisting of one contemporaneous reference vaccine 
strain. Whereas all the Kenyan influenza A/H3N2 viruses 
spanning the four year period of 2008-2011 clustered 
with the WHO recommended vaccine strain 
A/Brisbane/10/2007, none of these Kenyan influenza 
A/H3N2 HA1 sequences clustered with the 
A/Perth/16/2009 vaccine strain.  Furthermore, an 
interesting clustering pattern was noticed in the 
phylogenetic tree whereby adamantane-
sensitive/resistant strains –previously defined by the 
N31S/S31N amino acid polymorphism in the M2 
protein– formed distinct groupings characterized by the 
following parallel mutations in the HA protein: F193S & 
T140K for the sensitive strains and S193F & K140T for 
the resistant ones. In addition all the A/H3N2 virus 
strains from Kenya possessed D225N substitution 
(Figure 3). 
Phylogenetic analysis of the of the 52 A/H1N1pdm09 
Kenyan strains based on  HA1 sequences in relation to 
global and reference viruses, (Figure 4) showed that all 
the Kenyan viruses, together with majority of the global 
strains, had S203T amino acid substitution which is a 
parallel mutation in the HA protein previously associated 
with adamantine resistance in this influenza subtype 
(Garten et al, 2009). 
The tree topology for HA1 protein sequences of the 
Kenyan influenza A/H1N1 viruses (Figure 5) revealed 2 
main clusters, one containing glutamic acid at position  
140 (E140) of the HA1 protein and the other with a lysine 
substitution at this locus (E140K). All the influenza 
A/H1N1 virus strains obtained from Kenya between 
2008 and 2009 clustered together with global viruses 
that circulated after 2007 and lacked this amino acid 
substitution. The vaccine strains, A/Solomon 
Island/3/2006 and A/Brisbane/59/2007, clustered 
together with the strains from Kenya characterized by 
the E140K change amongst other global strains. In this 
study, we found that the E140K in the HA is a parallel 
mutation with S31N in M2 of influenza A/H1N1 viruses 
characteristic of resistance to adamantane. The amino 
acid substitution R192H was common among all the 
influenza A/H1N1 virus strains obtained from Kenya. 
4. Discussion 
In Kenya, resistance profiles to adamantane drugs 
amongst human influenza A viruses have remained 
undocumented, prompting us to investigate these 
patterns.  Whereas phenotypic and genotypic assays may 
be used for assessing resistance to adamantanes, the 
phenotypic assays are cumbersome because they first 
require viral propagation followed by determination of 
the drug 50% inhibitory concentration (IC50) values 
through plaque reduction assay (Zebedee & Lamb, 
1988). However, genotypic analysis of resistance to 
adamantane is simple because it focuses on only a few 
substitutions occurring at five codons within the M2 
gene (codons 26, 27, 30, 31 and 34) which are confirmed 
amantadine/rimantadine resistance markers (Abed et al, 
2005).  While adamantane drug resistance is known to 
be conferred by a single mutation in one of these five 
positions of the M2 protein of influenza A viruses (Abed 
et al, 2005), a preponderance of resistant strains are due 
to possession of the S31N substitution (Saito et al, 
2006b). In this study, we confirmed that where 
resistance occurred, the S31N / S31D mutation was the 
single most predominant marker of resistance found 
among influenza A virus strains that circulated in Kenya 
in the unique four year period between 2008-2011, 
when the three human influenza A subtypes co-
circulated in the country.  We found that following the 
global trend of decreasing resistance to adamantane, all 
Kenyan seasonal A/H1N1 viruses were sensitive to this 
class of drugs due to lack of all the molecular markers of 
drug resistance.  In contrast we found that all influenza 
A/H1N1pdm09 and A/H3N2 viruses were resistant to 
adamantanes due to the presence of S31N/S31D 
mutation in the M2 protein.  One unique A/H3N2 isolate 
had 80% substitutions in the region associated with 
adamantane resistance and is expected to have been 
highly resistant to adamantanes. 
The incidence of adamantane resistance among 
influenza A/H3N2 and seasonal influenza A/H1N1 
viruses has been on a rising trend (Hayden & de Jong, 
2011) (Deyde et al, 2007) (Saito et al, 2008), while the 
influenza A/H1N1pdm09 subtype was resistant to this 
class of drugs from the onset (Hayden & de Jong, 2011). 
Amongst the two subtypes, the progression in resistance 
to adamantanes has remained significantly high reaching 
90% among A/H3N2 obtained in Asia between 2005 and 
2006 season and remaining at 100% for A/H1N1pdm09 
since 2009 (Hayden & de Jong, 2011). Seasonal influenza 
A/H1N1 viruses showed a significant rise of up to 64% 
in terms of resistance in Asia to adamantanes during the 
same period.  Beyond 2006, an inverse pattern has been 
seen worldwide with a decrease in the resistance pattern 
among seasonal influenza A/H1N1 viruses depicting a 
15% in the antiviral resistance (Deyde et al, 2007) (Saito 
et al, 2008).  This pattern of resistance for seasonal 
A/H1N1 showed a complete reversal to resistance where 
we have shown that by 2008, all seasonal A/H1N1 
strains circulating in Kenya regained 100% sensitivity to 
adamantanes.  Since the year 2009 resistance to 
adamantanes among influenza A/H1N1pdm09 has 
remained notably high (Hayden & de Jong, 2011). These 
trends were confirmed for the Kenyan A/H1N1pdm09 
viruses where all the viruses tested had the S31N marker 
and were therefore resistant to adamantane.   
The findings of the present study indicate a continuing 
trend of resistance to adamantane among 
A/H1N1pdm09 and A/H3N2 influenza virus strains 
globally. In fact, resistance to adamantane in Kenya 
peaked at 100% for both influenza A/H3N2 and 
influenza A/H1N1pdm09 from 2008-2011. In a previous 
Kenyan study, we reported that the seasonal influenza 
A/H1N1 was completely replaced by the A/H1N1pdm09 
strain once the pandemic strain arrived in the country in 
mid 2008 (Majanja et al, 2013). By the time this subtype 
displacement occurred in Kenya, all the AH3N2 had 
become resistant to adamantane.   
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Figure 4: Phylogenetic tree analysis of HA1 amino acid sequences of influenza A/H1N1pdm09 strains obtained between 
2009 and 2011.  
The vaccine strain A/California/07/2009, global strains and local strains are indicated in red, black and blue colours 
respectively. Majority of the influenza A/H1N1pdm09 strains including those from Kenya possessed the S203T 
substitution common in all N-lineage influenza A viruses. Additional mutations V47I, A48S N129D, V30A, and S185T 
were noted among Kenyan strains and a few of the global strains. 
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Figure 5: Phylogenetic tree of HA1 amino acid sequences of influenza A/H1N1.  
The vaccine strains A/Solomon Island/3/2006 and A/Brisbane/59/2007 are highlighted in red. Global and local strains 
are shown in black and blue colours respectively. The tree topology for HA1 protein sequences of influenza A/H1N1 
revealed 2 main branches: One branch with glutamic acid residue at position140 (E140) of the protein sequence and 
another with Lysine amino acid (E140K) substitution at the same locus. Influenza A/H1N1 virus strains from Kenya 
lacked the E140K amino acid substitution. In addition they did not possess S31N marker of adamantane drug resistance 
in the M2 protein sequence. 
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strains carrying the resistance genotypes from 
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strains due to their increased fitness. In fact, it has been 
documented that such drug resistance can emerge even 
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reassortment (Hayden & de Jong, 2011).  
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lineage of swine A/H3N2 appearing in a child in Hong 
Kong in 1999 (Gregory et al, 2001).  Exchange of the M 
segment between the A/H1N1pdm09 is common and has 
previously been documented in Kenya (Bulimo et al, 
2012).  Analysis of HA1 protein segment of the Kenyan 
and global Influenza A/H3N2 viruses revealed distinct 
parallel S193F & K140T mutations for all virus strains 
(also referred to elsewhere (Saito et al, 2006a) as Clade 
N viruses) that also possessed the marker of drug 
resistance S31N in the M2 transmembrane protein 
sequence. These S193F and K140T mutations in HA1 
protein of A/H3N2 viruses have previously been 
associated with adamantane-resistance (Saito et al, 
2006a).  Further phylogenetic analysis of the HA1 genes 
indicated presence of D225N substitution in all influenza 
A/H3N2 drug resistant virus strains from Kenya and 
other regions of the world.  Strains that were depicted as 
sensitive in relation to adamantane possessed either the 
N225D or N225G substitution in the HA1 protein 
sequence. The findings from this study indicate a slight 
departure from those reported by Deyde (Deyde et al, 
2007) in which both resistant and sensitive strains 
possessed N225 and G225 mutations. However, the 
findings in this study are in harmony with those of Saito 
et al, (Saito et al, 2006a) which indicated possession of 
S193F and D225N substitution in the HA1 protein 
segment of amantadine resistant viruses.  
Analysis of the HA1 protein segment of all 
A/H1N1pdm09 virus isolates from Kenya from 2009 to 
2011 showed that they belonged to Clade 7 
characterized by signature S203T substitution (Garten et 
al, 2009). All the other regional and global virus 
sequences analyzed with the exception of only three 
strains: A/California/07/2009, 
KJ026377/Cameroon/2011, CY071818/ETH/2009 and 
CY039893/New York/2009 indicated presence of the 
same amino acid substitution. Significantly, the D222G 
and D239G substitutions in the HA1 protein associated 
with severe disease were not observed in any of the 
sequences analyzed (Kilander et al, 2010).  
In a previous study, the S31N drug resistant genotype in 
the M2 gene was associated with R192M substitution in 
the HA1 gene of seasonal influenza A/H1N1 (Saito et al, 
2008). Our findings regarding the Kenyan influenza 
A/H1N1virus strains in the study period indicated all the 
Kenyan isolates had the R192H amino acid change. This 
result negates the importance of a parallel mutation at 
position 192 in the HA1 as a contributor to resistance to 
adamantane in seasonal A/H1N1 strains.  Overall, the 
study indicates that the codon 140 of HA1 gene in both 
seasonal A/H1N1 and A/H3N2 viruses is important in 
categorizing drug resistance to adamantane whereby 
E140K is associated with resistance and K140E is 
associated with sensitivity to adamantanes.  
In assessing resistance to anti-influenza drugs, 
phenotypic assays are the gold standard.  Such assays 
require viral culture prior to determination of the drug 
50% inhibitory concentration (IC50) value. For the 
adamantane, IC50 values are assessed by the 
conventional plaque reduction assay.  A major weakness 
of the present study was the lack of phenotypic data to 
correlate the drug sensitivities with the genotypic 
analyses of the M2 gene.  Nonetheless, this is an 
important study because it for the first time, analyzed 
resistance to adamantane by the three human influenza 
A subtypes that circulated in the human population in 
Kenya in a  time period of four years when for once, the 
three subtypes co-circulated. 
5. Conclusion 
All the seasonal influenza A/H1N1 isolates obtained 
from Kenya during the study period were sensitive to the 
adamantane class of drugs due to possession of serine 
amino acid residues at position 31 of the M2 proteins. In 
contrast both influenza A/H3N2 and A/H1N1pdm09 
viruses were resistant to adamantane due to presence of 
asparagines at this locus. Thus, during the study period, 
Amantadine and Rimantadine were inappropriate for 
prophylaxis and treatment of influenza disease caused 
by A/H3N2 and A/H1N1pdm09 virus subtypes in Kenya.  
The findings of this study highlight the importance of 
continued surveillance of drug resistant genotypes 
amongst influenza A viruses.  Continued surveillance of 
drug resistance is recommended in order to monitor 
emergence of dangerous resistant strains and inform 
epidemic/pandemic preparedness and drug use policy. 
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